aTyr Pharma, Inc. (NASDAQ:ATYR) Receives Consensus Rating of “Hold” from Brokerages

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR) have earned a consensus rating of “Hold” from the eight brokerages that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $23.25.

A number of equities analysts recently commented on the company. Wells Fargo & Company restated an “equal weight” rating on shares of aTyr Pharma in a report on Monday, September 15th. Cantor Fitzgerald downgraded shares of aTyr Pharma from an “overweight” rating to a “neutral” rating in a research report on Monday, September 15th. Leerink Partnrs lowered shares of aTyr Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 15th. Jones Trading cut shares of aTyr Pharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of aTyr Pharma in a report on Monday, December 29th.

Institutional Investors Weigh In On aTyr Pharma

Hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System purchased a new stake in aTyr Pharma in the second quarter worth $28,000. Ameritas Investment Partners Inc. bought a new stake in shares of aTyr Pharma during the 2nd quarter valued at $45,000. Legal & General Group Plc purchased a new stake in shares of aTyr Pharma in the 2nd quarter worth about $49,000. Prudential Financial Inc. bought a new position in shares of aTyr Pharma in the 2nd quarter worth about $63,000. Finally, Oxford Asset Management LLP bought a new position in shares of aTyr Pharma in the 2nd quarter worth about $70,000. 61.72% of the stock is currently owned by institutional investors.

aTyr Pharma Trading Down 2.9%

aTyr Pharma stock opened at $0.73 on Friday. The firm has a market cap of $71.05 million, a P/E ratio of -0.87 and a beta of 0.60. aTyr Pharma has a 1-year low of $0.64 and a 1-year high of $7.29. The firm has a 50-day moving average of $0.76 and a 200-day moving average of $2.71.

aTyr Pharma (NASDAQ:ATYR) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). The business had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.91 million. Research analysts forecast that aTyr Pharma will post -0.91 earnings per share for the current fiscal year.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.